Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.57 |
| ▸ | PI4KA | P42356 | 1/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.57 |
| ▸ | ADA | P00813 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 10/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.51 |
| ▸ | CDK2 | P24941 | 7/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24236859 | 0.88 | ADA (0.54) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22326755 | 0.83 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL784184 | 0.80 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL3510456 | 0.79 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL18510393 | 0.79 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL23547298 | 0.79 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL25001340 | 0.77 | ADA (0.64) | ADASMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL18510390 | 0.76 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL18510360 | 0.76 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL18510385 | 0.76 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-23 | — | — | US | disclosed |
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-12031178-B2 | Cyclooctatetraene containing dyes and compositions | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-09 | — | — | US | disclosed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110237529-A1 | Adenosine Analogs and Their Use | MICRODOSE THERAPEUTX, INC | 2011-09-29 | — | — | US | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ADORA2A 385/4885ADORA1 446/4885ADORA2B 827/4885 |
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | BLVRB, BCDIN3D, FOSB | ADORA2A 3304/4885ADORA1 3504/4885ADORA2B 954/4885 |
| US-20110237529-A1 | Adenosine Analogs and Their Use | P2RY2, P2RY1, P2RY11 | ADORA2A 8/4885ADORA1 12/4885ADORA2B 19/4885 |
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PAICS, DPYD, PNP | ADORA2A 708/4885ADORA1 815/4885ADORA2B 369/4885 |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | ADORA2A 877/4885ADORA1 2126/4885ADORA2B 1054/4885 |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ADAR, AGO2, METTL16 | ADORA2A 422/4885ADORA1 608/4885ADORA2B 780/4885 |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | CHI3L1, CHIA, CHI3L2 | ADORA2A 3823/4885ADORA1 2776/4885ADORA2B 3889/4885 |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | ADORA2A 472/4885ADORA1 625/4885ADORA2B 288/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | ADORA2A 116/4885ADORA1 295/4885ADORA2B 412/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | ADORA2A 205/4885ADORA1 189/4885ADORA2B 305/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | ADORA2A 195/4885ADORA1 343/4885ADORA2B 454/4885 |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | ADORA2A 222/4885ADORA1 268/4885ADORA2B 406/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | ADORA2A 4836/4885ADORA1 4839/4885ADORA2B 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.